Contrary to initial expectations, angiogenesis inhibitors can cause toxicities in patients with
cancer. The toxicity profiles of these inhibitors reflect the disturbance of growth factor …

Emerging evidence supports a novel view of hypertension as a disease of inadequate or
aberrant responses to angiogenic growth factors (AGF). Patients with hypertension have …

Inhibitors of angiogenic factors are known to be upregulated, and their levels increase in the
maternal circulation before the onset of preeclampsia. We reproduced a previously …

Background: We evaluated bevacizumab with metronomic etoposide among recurrent
malignant glioma patients in a phase 2, open-label trial. Methods: A total of 59 patients …

Hypertension is considered a major public health issue due to its high prevalence and
subsequent risk of cardiovascular and kidney diseases. Thus, the search for new …

All living beings continue their life by receiving energy and by excreting waste products. In
animals, the arteries are the pathways of these transfers to the cells. Angiogenesis, the …

The ability to control cellular processes and precisely direct cellular reprogramming has
revolutionized regenerative medicine. Recent advances in in vitro transcribed (IVT) mRNA …

Inhibiting the actions of VEGF is a new therapeutic paradigm in cancer management with
antiangiogenic therapy also under intensive investigation in a range of nonmalignant …

Angiogenesis has long been a desired therapeutic approach to improve clinical outcomes of
conditions typified by ischemia. Vascular endothelial growth factor (VEGF) has …

The first aim of our study was to develop a pregnant mouse model for preeclampsia using
adenoviral vector containing mouse full-length soluble fms-like tyrosine kinase 1 (sFlt-1) but …